lisofylline has been researched along with Hyperglycemia, Postprandial in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolick, DT; Hatley, ME; Hedrick, CC; Nadler, JL; Srinivasan, S | 1 |
1 other study(ies) available for lisofylline and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Lisofylline, a novel antiinflammatory compound, protects mesangial cells from hyperglycemia- and angiotensin II-mediated extracellular matrix deposition.
Topics: Angiotensin II; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Connective Tissue Growth Factor; Cyclic AMP Response Element-Binding Protein; Extracellular Matrix; Extracellular Matrix Proteins; Fibronectins; Gene Expression; Glomerular Mesangium; Glucose; Humans; Hyperglycemia; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pentoxifylline; Phosphorylation; Transforming Growth Factor beta; Vasoconstrictor Agents | 2003 |